Answers are grounded in this paper and cite their sources.
Leukopenia is clearly the single most important risk factor for infection in cancer patients. We investigated the clinical usefulness of Z-100, a polysaccharide-rich extract from the Mycobacterium tuberculosis strain Aoyama B, on the protection of infection in patients with leukopenia induced by radiotherapy for lung cancer. This study was designed as a placebo-controlled double-blind clinical trial and was performed from April 1995 to September 1998. A total of 428 patients were preregistered before radiotherapy, and finally 65 patients with a leukopenia of less than 3, 000/mm3 were enrolled in the study. The average level of the white blood cell count had been higher in the Z-100 group since 4 weeks from administration but the difference was not statistically significant. The frequency of infection was 6.7% in the Z-100 group (n=30) and 21.2% in the control group (n=33) . The accumulated occurrence of infection was significantly higher in the control group since 4 weeks and thereafter. When the patients were classified as “definitely infected”, “possibly infected” (febrile with CRP> 3 mg), and “not infected”, the occurrence of infection was significantly less frequent in the Z-100 group by the Mantel test. These results suggest that Z-100 is useful in preventing the occurrence of infection induced by leukopenia, possibly by increasing the number of leukocytes as well as by other immunological reactivating mechanisms.
No takes yet. Share an insight, caveat, or question.
Kobayashi et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: